Chemotherapy of malignant tumors — A self-defeating form of immunotherapy?

Laursen, M L

doi:10.1016/0306-9877(89)90159-x

Cited by 3 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The decreases in humoral immunity and cellular immunological competence enable opportunistic infection and have a major influence on the host's prognosis. Since the tumor-bearing host per se is in a hypo-immunocompetent state, it may be necessary to discontinue treatment because of further deterioration of immunological competence due to administration of anticancer agents (44). Therefore, innovations in the maintenance of host immunological competence appear to be needed.…”

Section: Discussionmentioning

confidence: 99%

Establishment of combined immuno-chemotherapy with systemically administered gemcitabine and intra-portal administration of interleukin-2 in murine models of liver metastases of pancreatic cancer

Ito

Aiura²,

Ueda³

et al. 2008

Int J Oncol

View full text Add to dashboard Cite

Abstract. Despite attempts to use multiple drug combinations that include gemcitabine (GEM), there is very little evidence that these combination regimens are superior to the single use of this agent. We therefore investigated the suppressive effect of the combination of systemically administered GEM and locally administered interleukin-2 (IL-2) on liver metastasis in pancreatic cancer. Tumor-bearing mice were randomly divided into four groups: a control group, an IL-2 intrasplenic (is) administration group, a GEM intraperitoneal (ip) administration group, and a GEM ip+IL-2 is group. Liver weight, liver metastases, and tumor diameter (as assessed by the Winn assay) were compared among groups. Liver weight was significantly lower in the GEM+IL-2 group than in the control and IL-2 groups. The number of liver metastases was significantly reduced in the GEM+IL-2 group compared with all other groups. Splenocyte production of interferon-γ increased significantly in the GEM+IL-2 group after stimulation with Concanavalin A. Furthermore, tumor diameter was significantly reduced in the GEM+IL-2 group in the Winn assay when compared to that of the control group. These findings suggest that a combined regimen of GEM and portally administrated IL-2 might prevent liver metastasis in pancreatic cancer patients more effectively than current approaches and could prove useful as a postsurgical adjuvant therapeutic.

show abstract

Section: Discussionmentioning

confidence: 99%

Establishment of combined immuno-chemotherapy with systemically administered gemcitabine and intra-portal administration of interleukin-2 in murine models of liver metastases of pancreatic cancer

Ito

Aiura²,

Ueda³

et al. 2008

Int J Oncol

View full text Add to dashboard Cite

show abstract

Problems in the investigational study and clinical use of cancer immunotherapy

Osband

Ross

1990

Immunology Today

View full text Add to dashboard Cite

Combination Chemotherapy with Cyclophosphamide, Fluorouracil, and Either Epirubicin or Mitoxantrone: a Comparative Randomized Multicenter Study in Metastatic Breast Carcinoma

Periti

Pannuti

Cuna³

et al. 1991

Cancer Investigation

View full text Add to dashboard Cite

From February 1987 to January 1989, 60 patients with advanced breast cancer and no prior chemotherapy for advanced disease were randomized and studied, with 31 treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) and 29 patients with fluorouracil, mitoxantrone, and cyclophosphamide (FNC). Doses were 500 mg/m2 fluorouracil, 500 mg/m2 cyclophosphamide, and 50 mg/m2 epirubicin2 or 10 mg/m mitoxantrone, i.v. Day 1 every 3 weeks. There were no statistically significant differences in pretreatment patient characteristics between the groups. Fifty-six patients were evaluable for response (29 in the FEC arm and 27 in the FNC arm). The response rates were 48.2% for the FEC group (complete response (CR) 10.3% and partial response (PR) 37.9%) and 40.7% for the FNC group (CR 3.7% and PR 37%) (not significantly different, NS). The median response duration was 247 and 267 days, respectively (NS), the median time to progression and time to treatment failure was 244 and 155.5 days for the FEC group and 86 and 98 days for the FNC group, respectively (NS). The incidence of nausea/vomiting was 87.1% in the FEC group and 79.3% in the FNC group, with comparable severity. Alopecia occurred in 80.6% of FEC patients and 44.8% of FNC patients (p less than 0.05). The incidences and degrees of severity of leukopenia, anemia, and cardiotoxicity were comparable in the two treatment groups. Efficacy and toxicity of the two regimens were quite similar. FNC can improve the quality of life of patients by providing significantly less alopecia.

show abstract

Chemotherapy of malignant tumors — A self-defeating form of immunotherapy?

Cited by 3 publications

References 14 publications

Establishment of combined immuno-chemotherapy with systemically administered gemcitabine and intra-portal administration of interleukin-2 in murine models of liver metastases of pancreatic cancer

Establishment of combined immuno-chemotherapy with systemically administered gemcitabine and intra-portal administration of interleukin-2 in murine models of liver metastases of pancreatic cancer

Problems in the investigational study and clinical use of cancer immunotherapy

Combination Chemotherapy with Cyclophosphamide, Fluorouracil, and Either Epirubicin or Mitoxantrone: a Comparative Randomized Multicenter Study in Metastatic Breast Carcinoma

Contact Info

Product

Resources

About